Well, the FDA disagree almost the entire MSB hotcopper board. They are clear that Mesoblast do NOT have Orphan drug designation for adults, let alone High-Risk adults with aGvHD: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=214805
Good luck with treating 15 kids each quarter - at least your exit liquidity at lower and lower prices is good!
Ann: CYP-001s FDA Approval Pathway Not Impeded, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.5¢ | $38.44K | 230.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 277685 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 9872 | 2 |
View Market Depth
| Last trade - 14.35pm 16/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |